Ubiquinol (Reduced COQ10) for Patients With Sepsis

Completed · Phase 2 · Has a placebo group

Conditions studied: Sepsis

In brief

This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.

Key facts

Study ID

NCT01948063

Run by

Beth Israel Deaconess Medical Center

People needed

38

Starts

2012-10-01

Expected to finish

2014-04-01

Last updated by the study team

2017-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Over 18 years old
• Suspected or confirmed infection
• Presence of 2 or more systemic inflammatory response syndrome (SIRS) criteria
• Admission to the ICU

You may not qualify if…

• Under 18 years old
• Current CoQ10 supplementation
• Unable to receive enteral medications
• Would need a nasogastric or orogastric tube solely for the purposes of the study
• Pregnancy, incarceration, mentally disability
• Patient confirmed Comfort measures only, Do not resuscitate (DNR) and/or Do not intubate. Patients with DNR but intubated and being provided full care are eligible

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.